Catalent Financial Statements From 2010 to 2024
| 0C8 Stock | EUR 59.93 0.29 0.48% |
Check Catalent financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalent's main balance sheet or income statement drivers, such as , as well as many indicators such as . Catalent financial statements analysis is a perfect complement when working with Catalent Valuation or Volatility modules.
Catalent |
Catalent Company Current Valuation Analysis
Catalent's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Catalent Current Valuation | 11.57 B |
Most of Catalent's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Catalent is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Catalent has a Current Valuation of 11.57 B. This is 19.43% lower than that of the Healthcare sector and 55.65% higher than that of the Drug Manufacturers - Specialty & Generic industry. The current valuation for all Germany stocks is 30.39% higher than that of the company.
Catalent Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Catalent's current stock value. Our valuation model uses many indicators to compare Catalent value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Catalent competition to find correlations between indicators driving Catalent's intrinsic value. More Info.Catalent is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers reporting about 0.47 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Catalent is roughly 2.13 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Catalent's earnings, one of the primary drivers of an investment's value.About Catalent Financial Statements
Catalent stakeholders use historical fundamental indicators, such as Catalent's revenue or net income, to determine how well the company is positioned to perform in the future. Although Catalent investors may analyze each financial statement separately, they are all interrelated. For example, changes in Catalent's assets and liabilities are reflected in the revenues and expenses on Catalent's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Catalent. Please read more on our technical analysis and fundamental analysis pages.
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey. Catalent operates under Drug Manufacturers - Specialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 11000 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Catalent Stock
When determining whether Catalent is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Catalent Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Catalent Stock. Highlighted below are key reports to facilitate an investment decision about Catalent Stock:Check out the analysis of Catalent Correlation against competitors. For more detail on how to invest in Catalent Stock please use our How to Invest in Catalent guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.